Increased risk of type 2 diabetes in noncirrhotic patients with chronic hepatitis C virus infection.

OBJECTIVES: To investigate whether patients with chronic hepatitis C virus (HCV) infection without evidence of cirrhosis have an increased risk of diabetes mellitus (DM) and to evaluate possible risk factors for diabetes in this group. PATIENTS AND METHODS: We conducted a case-control study of 45 consecutive eligible patients with HCV infection and no clinical, scintigraphic, or histological evidence of cirrhosis, and a control group of 90 subjects without liver disease matched by age, sex, and body mass index and similar in their origin distribution. Eighty-eight patients with chronic hepatitis B virus (HBV) infection with no evidence of cirrhosis were also evaluated. The diagnosis of diabetes was based on the 1997 American Diabetes Association criteria. RESULTS: Fifteen patients (33%) with HCV infection were found to have type 2 diabetes compared with 5.6% in the control group without liver disease (P < .001) and 12% in the group with HBV infection (P = .004). Comparison of the patients with and without diabetes revealed that positive family history of diabetes, HCV 1b genotype, and a more severe liver histology were significantly associated with DM. CONCLUSIONS: Patients with chronic HCV infection have an increased prevalence of type 2 diabetes, and this prevalence is independent of cirrhosis. The pathogenesis is intriguing, appears to be unique to HCV, and requires further study.

Nifedipine in the treatment of severe preeclampsia.

We conducted a randomized clinical trial in which patients with severe preeclampsia between 26-36 weeks of gestation received either nifedipine (10-30 mg sublingually, then 40-120 mg/day orally; N = 24) or hydralazine (6.25-12.5 mg intravenously, then 80-120 mg/day orally; N = 25). Effective control of blood pressure was achieved with nifedipine in 95.8% of subjects and with hydralazine in 68%, a statistically significant difference (P less than .05). Maternal side effects were minor in both groups. Acute fetal distress developed in one nifedipine subject and in 11 treated with hydralazine. Mean prolongation of gestation was 15.5 +/- 10 days with nifedipine and 9.5 +/- 11 days with hydralazine, a difference that did not reach statistical significance (P less than .07). Infants born to women treated with nifedipine were delivered at more advanced gestational ages (34.6 +/- 2.3 versus 33.6 +/- 2.4 weeks; statistically not significant), weighed more (1826 +/- 456 versus 1580 +/- 499 g; statistically not significant), and tended to have fewer, mainly minor, complications. The average number of days spent in the neonatal intensive care unit was significantly lower in the nifedipine group (15.1 versus 32.7 days; P less than .005), leading to an average 31% reduction in total (maternal and neonatal) hospitalization-related charges for each nifedipine-treated pregnancy. We conclude that nifedipine is an effective, convenient, and low-cost treatment for patients with severe preeclampsia, and is not associated with undesirable side effects.

[Acute acalculous cholecystitis].

A previously healthy 32-year-old man presented with fever, upper abdominal pain and leukocytosis of 5 days duration. Ultrasonography and CT-scan of the abdomen were not diagnostic. On laparotomy acute gangrenous acalculous cholecystitis was found and was successfully treated by cholecystectomy. This condition is a well-known complication in critically ill patients. However, physicians should be aware of its possible occurrence even in previously healthy ambulatory patients, since a delayed diagnosis carries a significant risk of perforation and death.

Lymphocytic meningitis as the sole manifestation of Q fever.

A young man who presented with a 3 week history of fever and severe headache accompanied by mild leukocytosis, was found to have lymphocytic meningitis due to Coxiella burnetti. Thus, Q fever can present as lymphocytic (aseptic) meningitis responsive to tetracycline with no evidence of pulmonary involvement.

Cholelithiasis and pancreatic cancer. A case-control study.

To study the possible association between pancreatic cancer and cholelithiasis, we conducted a retrospective case-control study. Abdominal ultrasound of 100 consecutive cases of pancreatic cancer and that of 140 age- and gender-matched control subjects were examined by 2 observers who did not know the diagnosis. Thirty-seven patients with pancreatic cancer had cholelithiasis (37%), as compared with 23 (16%) of the control group (p < 0.001). The increased prevalence of gallstones in patients with pancreatic carcinoma remained significant when either male or female patients were compared (p < 0.02), as well as in the various age groups studied. For example, 30 (43.5%) of 69 patients 65 years of age and older had cholelithiasis versus 21 (22%) of 95 control subjects (p < 0.005). Thus, patients with pancreatic cancer were found to have a higher prevalence of gallstone disease than expected in a matched control population (relative risk, 2.2; 95% confidence interval, 1.2-4.3). This finding does not establish a causal link; however, the possibility should be pursued, more so because gallstones have been identified previously as likely risk factors for cancer in other parts of the biliary-pancreatic tract.

Correlation between gold-induced enterocolitis and the presence of the HLA-DRB1*0404 allele.

OBJECTIVE: In recent years we have treated 4 rheumatoid arthritis (RA) patients who developed gold-induced enterocolitis, a well-recognized, although rare, complication of chrysotherapy. The aim of the present study was to seek any genetic predisposition for this complication. METHODS: HLA DNA typing was done on fresh white blood cells from the 4 patients. RESULTS: Three of the 4 patients (75%) exhibited the DRB1*0404 allele, whereas the prevalence of this allele among the Ashkenazi Jewish population of RA patients without colitis was 9.2% and 10.2% in 2 different studies. CONCLUSION: The results indicate that the DRB1*0404 may be associated with risk for the development of gold-induced enterocolitis in this population and suggest that HLA DNA typing should be considered in Jews who may be undergoing chrysotherapy.